FDA Flags J&J For Inadequate Oversight Of Consumer Devices
This article was originally published in The Rose Sheet
Executive Summary
Though the firm claims to have come a long way in improving management of OTC pharma quality control since its 2009/2010 recalls, a May 22 warning letter regarding post-market monitoring and pre-market notifications for K-Y moisturizers suggests consumer devices are not getting the same level of attention.
You may also be interested in...
U.S. Skin Care Is Bright Spot As J&J Consumer Sales Dip
Sales of Neutrogena brand skin-care products helped propel 2.7% growth in Johnson & Johnson’s U.S. skin-care division for fiscal 2012. However, global economic weakness led to an overall 2.6% drop for the firm’s skin-care business overall.
Skin Care Carries J&J Consumer Biz. In Quarter Marred By OTC Drug Recall
Johnson & Johnson's skin-care franchise helped offset weak oral-care sales and hampered over-the-counter and nutritionals business associated with a recall of Motrin, Tylenol and other products in the firm's fiscal 2010 first quarter
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.